Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

9476	Companies
185462	Keywords
117807	Articles
99312	Press releases

Home
Companies
Biophytis

BRIEF

published on 05/15/2025 at 07:05, 6 months 21 days ago

Biophytis Unveils Promising Obesity Treatment at ECO 2025

Biophytis Clinical Trials Obesity Treatment BIO101 ECO 2025
REGULATED PRESS RELEASE

published on 05/15/2025 at 07:00, 6 months 21 days ago

Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 2025 Presentation
Biophytis highlights innovative approach to obesity treatment at ECO 2025 presentation, showcasing promising results of BIO101 drug candidate targeting muscle loss in obese patients

Biophytis Obesity Treatment BIO101 ECO 2025 Muscle Loss
BRIEF

published on 04/25/2025 at 18:05, 7 months 9 days ago

Biophytis Delays Release of 2024 Financial Statements

Financial Statements Biophytis Refinancing 2024 Delay
REGULATED PRESS RELEASE

published on 04/25/2025 at 18:00, 7 months 9 days ago

Postponement of the publication of the annual financial statements
Biophytis announces postponement of annual financial statements publication due to refinancing operation. Company aims to release by end of May 2025

Financial Statements Biophytis 2024 Postponement Refinancing Operation
BRIEF

published on 04/22/2025 at 07:05, 7 months 13 days ago

Biophytis Aims for Enhanced Mobility in Obesity Treatment

Biophytis Obesity Treatment Muscle Preservation GLP-1 Therapies Biotechnology Market
REGULATED PRESS RELEASE

published on 04/22/2025 at 07:00, 7 months 13 days ago

Biophytis targets mobility restoration in patients with obesity
Biophytis strengthens position in developing treatments for age-related muscle function loss in obesity care by focusing on quality weight loss and mobility restoration with BIO101 and GLP-1 therapies

Biophytis Muscle Function Obesity Care Quality Weight Loss Mobility Restoration
PRESS RELEASE

published on 04/22/2025 at 06:59, 7 months 13 days ago

Biophytis targets mobility restoration in patients with obesity
Biophytis focuses on preserving muscle function in obesity patients treated with GLP-1 therapies by developing BIO101. The aim is to improve quality of weight loss and mobility

Biophytis BIO101 Obesity Muscle Function GLP-1 Therapies
BRIEF

published on 04/09/2025 at 07:05, 7 months 26 days ago

Biophytis Initiates Phase 2 OBA Clinical Trial for Obesity Treatment

Biophytis Obesity Treatment Clinical Trial BIO101 Partnership Goal
REGULATED PRESS RELEASE

published on 04/09/2025 at 07:00, 7 months 26 days ago

Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
Biophytis confirms the Phase 2 OBA Clinical Trial launch in obesity, continuing development of BIO101 to reduce muscle strength loss. Seeking pharmaceutical partner for co-development

Biophytis BIO101 Obesity Pharmaceutical Partner Phase 2 OBA Clinical Trial
PRESS RELEASE

published on 04/09/2025 at 06:59, 7 months 26 days ago

Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
Biophytis confirms the launch of the Phase 2 OBA Clinical Trial in Obesity in 2025. The study aims to evaluate the efficacy of BIO101 in reducing muscle strength loss caused by GLP-1 agonists in obese patients

Biophytis BIO101 Obesity Muscle Strength Phase 2 OBA Clinical Trial

Accesswire

Published on 12/05/2025 at 14:00, 8 minutes ago

Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 02:35, 11 hours 33 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 11 hours 38 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 13 hours 8 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 15 hours 3 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 13:45, 23 minutes ago

BingX Introduces Recurring Buy to Help Users Ride Out Crypto Market Swings
Published on 12/05/2025 at 13:00, 1 hour 8 minutes ago

Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 1 hour 8 minutes ago

Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 2 hours 3 minutes ago

Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 2 hours 8 minutes ago

CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre

Les Echos

Published on 12/05/2025 at 08:45, 5 hours 23 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 20 hours 8 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 20 hours 23 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 20 hours 24 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 7 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE